Report #2843188

Received May 29, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: CA
Recovered: Unknown
Vaccinated: Mar 1, 2025
Onset: Mar 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	5y9ca	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Shingrix Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) (batch number 5y9ca, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose in 2023). In MAR-2025, the patient received the 2nd dose of Shingrix. In MAR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 27-MAY-2025 The pharmacist reported that a female adult received Shingrix first dose back in 2023 (no additional data), but then her second dose was on march 2025 which led to lengthening of vaccination schedule. The vaccine administration facility was the same as primary reporter.